Factors associated with treatment nonadherence among US bipolar disorder patients

被引:154
作者
Baldessarini, Ross J. [1 ,2 ,3 ]
Perry, Richard [4 ]
Pike, James [4 ]
机构
[1] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Neurosci Program, Boston, MA 02115 USA
[3] Massachusetts Gen Hosp, McLean Hosp, Psychopharmacol Program & Int Consortium Bipolar, Boston, MA 02114 USA
[4] Adelphi Grp, Bollington, Cheshire, England
关键词
adherence; adverse effects; bipolar disorder; long-term treatment; prophylaxis; maintenance;
D O I
10.1002/hup.908
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective Since sustained treatment-adherence is often problematic and may limit clinical outcomes among bipolar disorder (BPD) patients, we sought risk factors to guide clinical prediction of nonadherence. Methods Data were from a 2005 US national sample providing questionnaire responses by 131 randomly selected prescribing psychiatrists and their adult BPD patients. We contrasted demographic and clinical factors in treatment-adherent versus nonadherent patients (strictly defined as missing >= 1 dose within 10 days) in univariate analyses followed by multivariate logistic-regression modeling. Results Of 429 DSM-IV BPD patients (79% type-I; 62% women; 17% minorities), 34% reported missing >= 1 dose of psychotropic medication within 10 days, 20% missed entire daily doses at least once, and only 2.5% missed all doses for 10 days. However, their prescribing psychiatrists considered only 6% as treatment-nonadherent. Factors significantly associated with nonadherence in multivariate modeling ranked: alcohol-dependence > youth > greater affective morbidity > various side effects >= comorbid obsessive-compulsive disorder >= recovering from mania-hypomania. Unrelated were sex, diagnostic subtype, and other comorbidities. Since most patients received >= 2 psychotropics, potential relationships between treatment-complexity and adherence were obscured. Conclusions Prevalent treatment-nonadherence among American BPD patients, and striking underestimation of the problem by prescribing clinicians may encourage increasingly complex treatment-regimens of untested value, but added expense, risk of adverse effects, and uncertain impact on treatment-adherence itself. Copyright (C) 2007 John Wiley & Sons, Ltd.
引用
收藏
页码:95 / 105
页数:11
相关论文
共 69 条
[1]  
[Anonymous], GOODMAN GILMANS PHAR
[2]  
[Anonymous], 2002, Polypharmacy in Psychiatry
[3]   Long-term combination therapy versus monotherapy with lithium and carbamazepine in 46 bipolar I patients [J].
Baethge, C ;
Baldessarini, RJ ;
Mathiske-Schmidt, K ;
Hennen, J ;
Berghöfer, A ;
Müller-Oerlinghausen, B ;
Bschor, T ;
Adli, M ;
Bauer, M .
JOURNAL OF CLINICAL PSYCHIATRY, 2005, 66 (02) :174-182
[4]  
Baldessarini RJ, 2004, NEUROPSYCHOPHARMACOL, V29, pS88
[5]  
BALDESSARINI RJ, 1994, B MENNINGER CLIN, V58, P224
[6]  
Baldessarini RJ, 2006, LITHIUM NEUROPSYCHIA, P465
[7]   Patterns of psychotropic drug prescription for US patients with diagnoses of bipolar disorders [J].
Baldessarini, Ross J. ;
Leahy, Leslie ;
Arcona, Stephen ;
Gause, Douglas ;
Zhang, Winnie ;
Hennen, John .
PSYCHIATRIC SERVICES, 2007, 58 (01) :85-91
[8]  
BARRIES NC, 2005, INT J CLIN PRACT, V59, P1017
[9]   Adherence to treatment in mood disorders [J].
Byrne, N ;
Regan, C ;
Livingston, G .
CURRENT OPINION IN PSYCHIATRY, 2006, 19 (01) :44-49
[10]   Use of combinations of antipsychotics: McLean Hospital inpatients, 2002 [J].
Centorrino, F ;
Fogarty, KV ;
Sani, G ;
Salvatore, P ;
Cincotta, SL ;
Hennen, J ;
Guzzetta, F ;
Talamo, A ;
Saadeh, MG ;
Baldessarini, RJ .
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2005, 20 (07) :485-492